$IMVT News

Immunovant (IMVT) Stock Looks Stretched On Book Value Alone

Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats

Immunovant Q1 2027 Earnings Call: Complete Transcript

Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next

Immunovant (IMVT) Just Gave Investors Something To Think About

Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

Roivant reports top-line data from IMVT-1402 CLE trial

Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program

Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows

Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant Ends Autoimmune Skin Disorder Program

Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint

Immunovant Q1 2027 Earnings Call: Complete Transcript

Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value

Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?

Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

Immunovant, Inc. Q1 2027 Earnings Call Summary